Pneumatic Tube System Versus Personnel Transport and the Hemolysis Index of Emergency Department Blood Samples: A Randomized, Split-Sample, Single-Blind Trial (PTS-HEMO-ED)
Hemolysis is the most common pre-analytical error in emergency department (ED) laboratory specimens and can lead to false elevation of intracellular analytes (potassium, LDH, AST, hemoglobin), resulting in misdiagnosis and unnecessary testing. Blood samples in the ED are transported to the laboratory either by pneumatic tube systems (PTS) or manually by personnel. Although PTS shortens turnaround time, the forces generated during transport may damage erythrocyte membranes and promote hemolysis. Evidence on whether PTS increases hemolysis compared with personnel transport is inconsistent, partly because existing studies use parallel-group designs that cannot control for between-subject biological variability, and partly because findings differ across PTS brands and configurations. The Sumetzberger Power Control PTS installed at Marmara University Pendik Training and Research Hospital (speed 4-5 m/s, 120 m, cushioned capsule) has not been prospectively validated for hemolysis risk. This study uses a randomized, split-sample (within-patient matched), single-blind design in which two simultaneously drawn yellow-cap tubes from the same patient are randomly allocated, one to PTS and one to personnel transport, thereby eliminating between-patient variability. The primary outcome is the Hemolysis Index (HI) category (ordinal scale 0-5 corresponding to free hemoglobin thresholds of <50, 50-99, 100-199, 200-299, 300-500, and >500 mg/dL). Secondary outcomes include the rate of clinically significant hemolysis (HI >= 1 / free Hb >= 50 mg/dL) and the correlation between transport time and HI.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
PNEUMATIC TUBE SYSTEM TECHNICAL SPECIFICATIONS
The installed pneumatic tube system is a Sumetzberger Power Control system (Sumetzberger, Austria). The transit line length between the Emergency Department phlebotomy station and the central clinical laboratory is approximately 120 meters. System operating speed is set at 4-5 m/s. Transport capsules are cushioned with internal foam padding to minimize mechanical impact forces. Average transit duration ranges between 50 and 90 seconds.
BLOOD COLLECTION PROTOCOL
Blood collection is performed by trained emergency department phlebotomists using standard venipuncture technique. Tubes are drawn from a single venipuncture in the standard order of draw: (1) blue-cap coagulation tube, not used in the study; (2) yellow-cap serum separator tube #1; (3) yellow-cap serum separator tube #2; (4-5) any additional clinically indicated tubes, not used in the study. The two yellow-cap serum separator tubes are dispatched simultaneously by the two transport routes and are analysed simultaneously on arrival at the laboratory, so that waiting time does not act as a pre-analytical variable.
RANDOMIZATION AND ALLOCATION CONCEALMENT (CONSORT 2025 Items 15-17)
Allocation is by computer-generated block randomization with a block size of four. The allocation sequence assigns each participant to Sequence A (tube #1 to the pneumatic tube system, tube #2 to personnel transport) or Sequence B (tube #1 to personnel transport, tube #2 to the pneumatic tube system). The sequence is held in sealed, opaque, sequentially numbered envelopes that are opened in order at the time of enrolment. This scheme balances any effect of tube draw order across the two transport routes.
BLINDING (CONSORT 2025 Item 12b)
Tubes are labeled with standardized participant study identifiers and tube sequence numbers (Tube #1 and Tube #2) without indicating transport allocation. Laboratory technicians operating the automated analyzer and assessing the Hemolysis Index remain fully blinded to transport allocation. Clinicians and investigators are not blinded.
WITHDRAWAL CRITERIA
A participant's tube pair is withdrawn from analysis if pneumatic transport cannot be completed because of system failure, if a tube is broken or otherwise cannot be analyzed, or if the participant withdraws consent.
HARMS (CONSORT 2025 Item 27)
No intervention is applied to the participant. Both tubes are drawn from the venipuncture already required for routine clinical care, and no additional venipuncture or other invasive procedure is performed. No participant-level adverse events are therefore anticipated and no harms outcome measure is specified.
PATIENT AND PUBLIC INVOLVEMENT (PPI) STATEMENT (CONSORT 2025 Item 8)
Patients or members of the public were not involved in the design, conduct, reporting, or dissemination plans of this research. PPI was deemed non-applicable given the technical, pre-analytical nature of this laboratory quality evaluation study.
DATA SHARING STATEMENT (CONSORT 2025 Item 4)
De-identified individual participant data collected during the trial will be made available upon reasonable request to the corresponding investigator following publication.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Emir Ünal, Assistant Professor
- Numero di telefono: +905327766010
- Email: emirunal@gmail.com
Backup dei contatti dello studio
- Nome: Emir Ünal, Assistant Professor
- Email: emirunal@gmail.com
Luoghi di studio
-
-
Pendik
-
Istanbul, Pendik, Turchia (Türkiye), 34899
- Reclutamento
- Marmara University Pendik Training and Research Hospital
-
Contatto:
- Emir Ünal
- Numero di telefono: 05327766010
- Email: emirunal@gmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults aged 18 years or older
- Presenting to the emergency department of Marmara University Pendik Training and Research Hospital
- Venous blood draw required for routine clinical care, allowing two yellow-cap (serum separator) tubes to be drawn from the same venipuncture
- Written informed consent provided by the participant or, where the acute clinical condition of the participant prevents this, by a legal representative
Exclusion Criteria:
- Known underlying hemolytic disorder (e.g., hemolytic anemia, sickle cell disease, G6PD deficiency, autoimmune hemolytic anemia, or TTP/HUS)
- Macroscopic hemolysis visible in the sample tube immediately after phlebotomy
- Age younger than 18 years
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Separare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Altro: PTS-First Sequence
Participants from whom two yellow-cap serum separator blood tubes are drawn simultaneously. Tube #1 (first drawn) is transported via the pneumatic tube system (PTS), and Tube #2 (second drawn) is transported by manual personnel. Both tubes are dispatched simultaneously. |
Blood sample transport using the Sumetzberger Power Control pneumatic tube system (Sumetzberger, Austria). The system operates at a speed of 4-5 m/s over a distance of approximately 120 meters using cushioned capsules. Transport duration ranges between 50 and 90 seconds. Blood sample transport performed manually by emergency department staff carrying the tube on foot from the phlebotomy area to the central clinical laboratory. Transport is dispatched simultaneously with the paired pneumatic tube sample. |
|
Altro: Personnel-First Sequence
Participants from whom two yellow-cap serum separator blood tubes are drawn simultaneously. Tube #1 (first drawn) is transported by manual personnel, and Tube #2 (second drawn) is transported via the pneumatic tube system (PTS). Both tubes are dispatched simultaneously. |
Blood sample transport using the Sumetzberger Power Control pneumatic tube system (Sumetzberger, Austria). The system operates at a speed of 4-5 m/s over a distance of approximately 120 meters using cushioned capsules. Transport duration ranges between 50 and 90 seconds. Blood sample transport performed manually by emergency department staff carrying the tube on foot from the phlebotomy area to the central clinical laboratory. Transport is dispatched simultaneously with the paired pneumatic tube sample. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Hemolysis Index (HI) Category in PTS-Transported vs. Personnel-Transported Tubes
Lasso di tempo: At laboratory analysis (within 30 minutes of blood draw)
|
Ordinal 6-category HI scale (0=<50, 1=50-99, 2=100-199, 3=200-299, 4=300-500, 5=>500 mg/dL free hemoglobin) as reported by the automated analyser. Higher category indicates more hemolysis. Compared between PTS and personnel tube from the same patient (paired). |
At laboratory analysis (within 30 minutes of blood draw)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Rate of Clinically Significant Hemolysis (HI ≥ 1) in PTS-Transported vs. Personnel-Transported Tubes
Lasso di tempo: At laboratory analysis (within 30 minutes of blood draw)
|
Proportion of tubes with HI category ≥ 1 (free haemoglobin ≥ 50 mg/dL), the threshold at which samples are typically flagged for rejection by the laboratory. Dichotomous outcome (0 vs ≥1) compared between matched tube pairs. |
At laboratory analysis (within 30 minutes of blood draw)
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Spearman Correlation Between Tube Transport Time and HI Category
Lasso di tempo: At laboratory analysis (within 30 minutes of blood draw)
|
Spearman rank correlation coefficient (ρ) between recorded PTS transport time (seconds, 50-90 s range) and the HI category of the PTS tube. Exploratory analysis. |
At laboratory analysis (within 30 minutes of blood draw)
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Emir Ünal, Marmara University
Pubblicazioni e link utili
Pubblicazioni generali
- Mullins GR, Bruns DE. Air bubbles and hemolysis of blood samples during transport by pneumatic tube systems. Clin Chim Acta. 2017 Oct;473:9-13. doi: 10.1016/j.cca.2017.08.008. Epub 2017 Aug 10.
- Kara H, Bayir A, Ak A, Degirmenci S, Akinci M, Agacayak A, Marcil E, Azap M. Hemolysis associated with pneumatic tube system transport for blood samples. Pak J Med Sci. 2014 Jan;30(1):50-8. doi: 10.12669/pjms.301.4228.
- Cakirca G, Erdal H. The Effect of Pneumatic Tube Systems on the Hemolysis of Biochemistry Blood Samples. J Emerg Nurs. 2017 May;43(3):255-258. doi: 10.1016/j.jen.2016.09.007. Epub 2017 Mar 28.
- Phelan MP, Reineks EZ, Hustey FM, Berriochoa JP, Podolsky SR, Meldon S, Schold JD, Chamberlin J, Procop GW. Does Pneumatic Tube System Transport Contribute to Hemolysis in ED Blood Samples? West J Emerg Med. 2016 Sep;17(5):557-60. doi: 10.5811/westjem.2016.6.29948. Epub 2016 Jul 26.
- Ding X, Wen X, Wang L, Chen T, Zhou G, He H, Xin X. Effects of a pneumatic tube system on the hemolysis of blood samples: a PRISMA-compliant meta-analysis. Scand J Clin Lab Invest. 2021 Sep;81(5):343-352. doi: 10.1080/00365513.2021.1930140. Epub 2021 Jun 10.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- MU-KAEK-2026-09.2029.26-0645
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
De-identified individual participant data collected during the trial that underlie the published results will be made available upon reasonable request to qualified scientific researchers.
Periodo di condivisione IPD
Data will become available beginning 3 months following publication and ending 36 months following article publication.
Criteri di accesso alla condivisione IPD
Proposals should be submitted to the corresponding investigator via email (emirunal@gmail.com). Requestors must provide a methodologically sound research proposal and sign a data use agreement.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .